Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 223 results for myocardial infarction

  1. Indicator advisory committee members

    Biographies and interests register for the indicator advisory committee

  2. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

    Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.

  3. Thoracoscopically assisted mitral valve surgery (IPG245)

    Evidence-based recommendations on thoracoscopically assisted mitral valve surgery. This involves repairing a defective valve through one or more small incisions between the ribs rather than one large incision through the breastbone (sternum).

  4. Cryoablation for atrial fibrillation in association with other cardiac surgery (IPG123)

    Evidence-based recommendations on cryoablation for atrial fibrillation in association with other cardiac surgery. This involves using a probe to freeze the heart tissue to scar it and interrupt the abnormal electrical signals.

  5. CentriMag for heart failure (MIB92)

    NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .

  6. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .

  7. Balloon valvuloplasty for aortic valve stenosis in adults and children (IPG78)

    Evidence-based recommendations on balloon valvuloplasty for aortic valve stenosis in adults and children. This involves inflating a balloon inserted into the narrow valve to widen it so that blood can flow out more easily.

  8. Cardiovascular disease prevention: cardiovascular risk assessment for people with bipolar, schizophrenia or other psychoses (IND150)

    This indicator covers the percentage of patients aged between 25 and 84 years with schizophrenia, bipolar affective disorder and other psychoses (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a full formal cardiovascular disease risk assessment performed in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM120

  9. E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)

    Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.

  10. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued [GID-TAG493]

  11. Cardiovascular risk assessment and lipid modification (QS100)

    This quality standard covers identifying and assessing cardiovascular risk in adults (aged 18 and over) and treatment to prevent cardiovascular disease. It describes high-quality care in priority areas for improvement.

  12. Type 2 diabetes in adults: management (NG28)

    This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

  13. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M

  14. NICE impact diagnostic pathology

    Find out more about the progress made in implementing NICE guidance on diagnostic pathology

  15. Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)

    Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.

  16. Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis (IPG777)

    Evidence-based recommendations on percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. This involves using a wire mesh tube called a stent to widen the narrowed carotid artery.

  17. Aspirin and anticoagulant treatment for acute ischaemic stroke: Does modified-release dipyridamole or clopidogrel with aspirin improve outcome compared with aspirin alone when administered early after acute ischaemic stroke?

    Clopidogrel, administered with aspirin, improves outcome after myocardial infarction. It is not known whether antiplatelet agents other...

  18. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

  19. What is the most clinically and cost-effective dual antiplatelet therapy for people aged 75 and over with an acute coronary syndrome, who are having percutaneous coronary intervention (PCI)?

    population having PCI, particularly for people with ST‑segment elevation myocardial infarction (STEMI). However, the summary of product...

  20. Type 2 diabetes in adults (QS209)

    This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.

  21. Delivering Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF) in Wirral

    population groups without a diagnosis of heart failure, such as post myocardial infarction or revascularisation to support an increase...

  22. Hypertension: Improving blood pressure management in primary care

    morbidity and mortality in the UK. It is a major risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease,...

  23. Endovascular stent insertion for intracranial atherosclerotic disease (IPG429)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

  24. Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (IPG380)

    Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.

  25. Transcatheter endovascular closure of perimembranous ventricular septal defect (IPG336)

    Evidence-based recommendations on transcatheter endovascular closure of perimembranous ventricular septal defect. This involves inserting a small blocking device (called an occluder) into the heart.

  26. Bed-based intermediate care: Somerset Care and Yeovil District Hospital

    reablement, transitional care, social care

  27. Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB53)

    NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  28. Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB54)

    NICE has developed a medtech innovation briefing (MIB) on the Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  29. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (IPG569)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

  30. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  31. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

  32. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

  33. Type 1 diabetes in adults (QS208)

    This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.

  34. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

    Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.

  35. COVID-19 ready rehabilitation for heart failure: REACH-HF can deliver

    CR, 39/90 (43%) did so only when heart failure was secondary to myocardial infarction or coronary revascularisation. Only 35/90 (39%)...

  36. Myocardial infarction with ST-segment elevation: acute management (CG167)

    This guideline has been updated and replaced by NICE guideline NG185.

  37. Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.

  38. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis

  39. Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation (IPG563)

    Evidence-based recommendations on percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation in adults. This involves destroying the tissue causing atrial fibrillation using laser energy.

  40. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

  41. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

    This guideline has been updated and replaced by NICE guideline NG185.

  42. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

  43. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  44. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

  45. Tocilizumab for treating giant cell arteritis (TA518)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.

  46. MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery (MIB323)

    NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .

  47. Gout: diagnosis and management (NG219)

    This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

  48. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.

  49. BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain (MTG4)

    In November 2016, NICE reviewed this guidance and recommended that it should be withdrawn. The guidance was published in June 2011 and recommended that further research was carried out on the technology. There was insufficient evidence on its use in clinical practice to recommend adoption. On reviewing the guidance in 2016, NICE determined that: The comparator in the original guidance, standard serial troponin testing, was changed in 2014 to high sensitivity troponin testing which expert advice indicated is now widespread in the NHS The clinical pathway in the original evaluation has significantly changed and the original scope is no longer valid. These changes mean that the current guidance is no longer valid and NICE would not be able to update it. The guidance has therefore been withdrawn. For a copy of the review decision please contact nice@nice.org.uk.